Management of patients with transvalvular right ventricular leads undergoing transcatheter tricuspid valve interventions: a scientific statement of the European Heart Rhythm Association and the European Association of Percutaneous Cardiovascular Inte
Up to one-third of patients referred for transcatheter tricuspid valve intervention (TTVI) have a transvalvular pacemaker (PPM) or implantable cardioverter-defibrillator (ICD) lead in place. Both the electrophysiology and interventional cardiology communities have been alerted to the complexity of decision-making in this situation due to potential interactions between the leads and the TTVI material, including the risk of jailing or damage to the leads. This document, commissioned by the European Heart Rhythm Association and the European Association of Percutaneous Cardiovascular Interventions of the ESC, reviews the scientific evidence to inform Heart Team discussions on the management of patients with a PPM or ICD who are scheduled for or have undergone TTVI.
Authors
- Julien Dreyfus (ORCID: https://orcid.org/0000-0003-1338-3007)
- Christophe Leclercq (ORCID: https://orcid.org/0000-0002-4399-5568)
- Jean‐Claude Deharo (ORCID: https://orcid.org/0000-0002-1534-3845)
- Nigel Lever (ORCID: https://orcid.org/0000-0002-4812-9001)
- Archana Rao (ORCID: https://orcid.org/0000-0002-3893-3944)
- Fabien Praz (ORCID: https://orcid.org/0000-0001-5416-165X)
- Maully J. Shah (ORCID: https://orcid.org/0000-0002-4743-6915)
- Michael Glikson (ORCID: https://orcid.org/0000-0001-5706-0395)
- Haran Burri (ORCID: https://orcid.org/0000-0002-4393-5338)
- Blandine Mondésert (ORCID: https://orcid.org/0000-0001-7777-5689)
- Antonio Mangieri (ORCID: https://orcid.org/0000-0002-3239-4046)
- Pascal Defaye (ORCID: https://orcid.org/0000-0002-7183-4278)
- Christoph Starck (ORCID: https://orcid.org/0000-0002-2753-1456)
- Maria-Grazia Bongiorni
Institutions
- University of Bern (CH)
- Western University (CA)
- Children's Hospital of Philadelphia (US)
- University of Liverpool (GB)
- University of Auckland (NZ)
- Inserm (FR)
- Aarhus University (DK)
- Charles University (CZ)
- Aix-Marseille Université (FR)
- Hospital of the University of Pennsylvania (US)
- Liverpool Heart and Chest Hospital NHS Trust (GB)
- Montreal Heart Institute (CA)
- Centre Hospitalier Universitaire de Grenoble (FR)
- London Health Sciences Centre (CA)
- University Hospital of Bern (CH)
- Auckland City Hospital (NZ)
- Shaare Zedek Medical Center (IL)
- Aarhus University Hospital (DK)
- Hospital Universitari i Politècnic La Fe (ES)
- Liverpool Heart and Chest Hospital (GB)
- Assistance Publique Hôpitaux de Marseille (FR)
- Centro de Investigación en Red en Enfermedades Cardiovasculares (ES)
- University Hospital of Zurich (CH)
- Lung Institute (US)
- University Hospital of Geneva (CH)
- NIHR Imperial Biomedical Research Centre (GB)
- Centro de Investigación Biomédica en Red (ES)
- Institut Cardiovasculaire Paris Sud (FR)
- Centrale Méditerranée (FR)
- Klinikum Links der Weser (DE)
- Grenoble Institute of Neurosciences (FR)
- Centre Cardiologique du Nord (FR)
- Centre Hospitalier Universitaire de Rennes (FR)
- University Hospital Kralovske Vinohrady (CZ)
- Hôpital de la Timone (FR)
- IRCCS Humanitas Research Hospital (IT)
- Université de Rennes (FR)
- Université de Montréal (CA)
- Technische Universität Dresden (DE)
- Charité - Universitätsmedizin Berlin (DE)
- University of Hong Kong (HK)
- Université Grenoble Alpes (FR)
Publication Details
- Journal
- EP Europace
- Published
- 2025-03-31
- DOI
- https://doi.org/10.1093/europace/euaf061
- Citations
- 23
- Primary Topic
- Cardiac Valve Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 31.93